Herpes Simplex Virus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Herpes Simplex Virus Treatment Market is segmented by Drug (Acyclovir, Valacyclovir, Famciclovir, and Other Drugs), Route of Administration (Oral, Injection, and Topical), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

Market Snapshot

Herpes Simplex Virus Treatment Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.71 %
Herpes Simplex Virus Treatment Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The herpes simplex virus treatment market was valued at USD 2,215.34 million in 2021, and it is expected to record a CAGR of 5.71 % over the forecast period.

The COVID-19 pandemic has significantly impacted market growth. The association of herpes simplex virus with the SARS-CoV-2 virus was established in many studies by the researcher, which impacted the market positively due to the rise in the demand of the anti-viral drugs for the treatment and further expected to drive growth in the studied market owing to the COVID-19 and its impact on the people with Herpes Simplex Virus (HSV). For instance, according to the research study published in July 2021, titled “Herpes simplex and herpes zoster viruses in COVID-19 patients”, herpes simplex virus type-1 and varicella-zoster viruses are strongly associated with COVID-19 infection. The prevalence of the herpes simplex virus type-1 occurrence in the COVID-19 group was 2.81% compared to 0.77% in the hospital population odds ratio of 5.27. Thus, there was a rise in demand for herpes simplex virus treatment in the ongoing pandemic. However, the COVID-19 pandemic led to disruption in the research and development activities of other therapies and drugs for medical conditions other than COVID-19 and impacted the treatment procedures and supply chain of the pharmaceuticals around the world, which impacted the herpes simplex virus treatment market.

The market's growth can be largely attributed to factors such as the growing burden of herpes simplex virus infections, including genital herpes, and increasing research and development activities. These factors are leading to increasing demand for herpes simplex virus treatment.

With the increasing burden of the herpes simplex virus (HSV) infections such as genital herpes, Herpes Simplex Virus type 1, and Herpes Simplex Virus type 2, around the world, the demand for HSV drugs and therapeutics is increasing rapidly, which is the prime factor expected to drive the growth of the herpes simplex virus treatment market around the world during the forecast period. Herpes Simplex Virus has two types, Herpes Simplex Virus -1 and Herpes Simplex Virus -2. According to a research study published in June 2021, titled “Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression”, in Asia (including the World Health Organization regions of Southeast Asia and the Western Pacific), about 1 in 10 person is infected with Herpes Simplex Virus type-2 infection, and Herpes Simplex Virus type-2 accounts for about half of the genital ulcer disease (GUD) cases and three-quarters of genital herpes cases, due to which there is a need for a Herpes Simplex Virus -2 vaccine and universal access to sexual and reproductive health services, which is expected to boost the growth of the herpes simplex virus treatment market during the forecast period. Hence, a higher prevalence of the herpes simplex virus is expected to boost market growth.

Increasing research and development activities are also contributing to market growth. There is high potential in the herpes simplex virus treatment market owing to the huge burden of the herpes simplex virus infections on the healthcare systems around the world, leading to huge investments in the research and development of effective therapeutics for the infections, which is expected to boost the growth of the studied market over the forecast period. For instance, in February 2021, the Federal Ministry of Education and Research (BMBF) provided funding of EUR 2.34 million to Dr. Florian Full at the Institute of Clinical and Molecular Virology at Universitätsklinkum Erlangen at Friedrich-Alexander-Universität (FAU) for the development of a new drug against the herpes virus. The funding is for the next five years. The study's outcome may impact the market positively and thus boost the growth in the studied market.

However, the social stigma associated with sexually transmitted diseases, coupled with rising product recalls, is one of the major factors impeding the market’s growth.

Scope of the Report

As per the scope of the report, herpes is a type of sexually transmitted disease caused by the herpes simplex virus. It is categorized into two: Herpes Simplex Virus-1, which is found around the mouth, and Herpes Simplex Virus-2, which is found around the genital area. The global herpes simplex virus treatment market is segmented by drug (acyclovir, valacyclovir, famciclovir, and other drugs), route of administration (oral, injection, and topical), and geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Drug
Acyclovir
Valacyclovir
Famciclovir
Other Drugs
By Route of Administration
Oral
Injection
Topical
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

Acyclovir Segment is Expected to Hold a Significant Market Share in the Herpes Simplex Virus Treatment Market

Acyclovir, marketed as Zovirax/Sitavig, is one of the most preferred anti-viral agents used for the treatment of herpes, which is primarily used against oral herpes and herpes simplex encephalitis (HSE). It is a purine nucleoside analog that enters viral DNA to restrict its replication process by converting it into acyclovir triphosphate.

According to the research study published in December 2019, titled “Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2”, omeprazole exerted substantially stronger effects on acyclovir activity and increased acyclovir activity at lower concentrations, which resulted in an increase in the acyclovir-mediated effects on herpes simplex virus 1 and 2 (HSV-1 and -2) replication in a dose-dependent manner. The synergic effect of other drugs with acyclovir will lead to increased adoption of low concentration acyclovir medications to achieve safety and thereby lead to higher adoption and further expected to rise in growth of this segment over the forecast period.

Additionally, the ongoing research and development in the area and the launch of new drugs in the segment by the market players will further augment the growth of the acyclovir segment in the herpes simplex virus treatment market over the forecast period. For instance, in November 2020, AmnealPharmaceuticals received approval for its Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax for treating recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.

In April 2019, Fera Pharmaceuticals received orphan drug exclusivity from the US Food and Drug Administration for Avaclyr (acyclovir ophthalmic ointment), 3% for the treatment of herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus. Therefore, due to the aforementioned factors, the acyclovir drug segment is expected to grow in the herpes simplex virus treatment market during the forecast period.

Herpes Simplex Virus Treatment Market Research

North America Holds a Significant Share in the Market and Expected to do Same Over the Forecast Period

North America is expected to be dominant in the genital herpes market owing to the growing prevalence of infections of the herpes simplex virus. According to the study published in Open Forum Infectious Diseases Journal titled 'Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050' published in April 2021, over the course of a century, the epidemic has evolved significantly, having the biggest impact on individuals aged 15 to 34. In addition to the 47 million illnesses that will be widespread in 2020, the high incidence will continue for the following three decades, with over 600,000 new infections occurring each year. The rising incidence of herpes simplex virus infections is expected to drive this market's growth in this region.

The research and development in the field and the increasing number of clinical trials are driving the market's growth. For Instance, in March 2021, Precision Vaccinations and GlaxoSmithKline (GSK) launched a limited Phase 1 clinical trial for a herpes simplex virus type 2 (HSV-2) candidate known as HSV vaccine (GSK4108771A). Thus, such advancements boost the growth of the region's studied market.

Hence, the rising burden of infections due to the herpes simplex virus, coupled with the rising awareness and new product launches, is expected to boost market growth over the forecast period.

Herpes Simplex Virus Treatment Market Analysis

Competitive Landscape

The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the companies that are currently dominating the market are GlaxoSmithKline LLC, Carlsbad Tech, Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., and Fresenius Kabi.

Recent Developments

  • In October 2021, United BioPharma collaborated with Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology to investigate the efficacy of UB-621, a best-in-class long-acting medication for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).
  • In July 2021, AiCuris Anti-infective Cures AG started the Phase III development of pritelivir, a new helicase-primase inhibitor, for acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definitions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Herpes Simplex Virus Infections such as Genital Herpes

      2. 4.2.2 Increasing Research and Development Activities

    3. 4.3 Market Restraints

      1. 4.3.1 Social Stigma Associated with Sexually Transmitted Diseases, Coupled with Rising Product Recalls

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Drug

      1. 5.1.1 Acyclovir

      2. 5.1.2 Valacyclovir

      3. 5.1.3 Famciclovir

      4. 5.1.4 Other Drugs

    2. 5.2 By Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Injection

      3. 5.2.3 Topical

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 United Kingdom

        2. 5.3.2.2 Germany

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Teva Pharmaceuticals Industries Ltd

      2. 6.1.2 Apotex Inc.

      3. 6.1.3 Viatris Inc.

      4. 6.1.4 Epi Health LLC

      5. 6.1.5 Zydus Cadila

      6. 6.1.6 GlaxoSmithKline PLC

      7. 6.1.7 Carlsbad Tech

      8. 6.1.8 Emcure Pharmaceuticals Ltd. (Avet Pharmaceuticals Inc.)

      9. 6.1.9 Glenmark Pharmaceuticals

      10. 6.1.10 Fresenius SE & Co. KGaA

      11. 6.1.11 AiCuris GmbH & Co. KG

      12. 6.1.12 Agenus Inc.

      13. 6.1.13 NanoBio Corporation

      14. 6.1.14 Novartis International AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Herpes Simplex Virus Treatment Market market is studied from 2019 - 2027.

The Global Herpes Simplex Virus Treatment Market is growing at a CAGR of 5.71% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Carlsbad Tech , Glenmark Pharmaceuticals Inc. , Fressenius Kabi , Emcure Pharmaceuticals Ltd. , GlaxoSmithKline LLC are the major companies operating in Global Herpes Simplex Virus Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!